Sidoti Starts VNUS Medical (VNUS) at Neutral
More News related to VNUS
- VNUS Medical Technologies to Present at Lazard Capital Markets 5th Annual Healthcare Conference
- VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
- VNUS Medical Technologies (VNUS) Tops Q3 View By 3c
- VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
- Lazard Capital Markets Starts VNUS Medical (VNUS) at Buy
More News related to New Coverage
- The Hartford (HIG) Talks About Its Highly Rated CMBS Portfolio
- PepsiCo (PEP) to Invest $3 Billion in Mexico Operations
- Quicksilver Resources (KWK) Announces '09 Capital Budget
- Cosi, Inc. (COSI) Forms Special Committee to Review Strategic Alternatives
- Par Pharmaceutical (PRX) Halts Shipments of of Budesonide Inhalation Suspension
Sidoti & Co. initiates coverage on VNUS Medical Technologies (Nasdaq: VNUS) with a Neutral rating.
VNUS Medical Technologies, Inc. provides medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition caused by incompetent vein valves in the legs.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
